Patent ID: 11912766
Assignee: ALLAKOS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC C

Claim 1:
2. The anti-Siglec-7 antibody of claim 1, wherein the variant Fc region comprises at least one amino acid modification, or at least two amino acid modifications, or at least three amino acid modifications that reduce effector function at a position selected from the group consisting of 232, 233, 234, 235, 236, 237, 238, 242, 259, 267, 268, 287, 292, 297, 302, 306, 309, 322, 323, 327, 328, 329, 330, 331, 332, and 334; and/or modifications at positions 252, 254, and 256 that increase antibody stability.